Monopar Therapeutics (MNPR) Interest Expenses (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Interest Expenses data on file, last reported at $22.2 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 24.46% year-over-year to $22.2 million; the trailing twelve-month figure through Dec 2025 stood at $22.2 million (up 24.46% YoY), and the FY2025 full-year result was $22.2 million, up 24.46% from the prior year.
• Interest Expenses advanced to $22.2 million in Q4 2025, from $110800.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $22.2 million in Q4 2025 to a low of $4.0 in Q1 2025.
• A 5-year average of $6.6 million and a median of $124090.0 in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 47.89% in 2021 and grew 19.07% in 2023, its largest moves.
• Tracing MNPR's Interest Expenses over 5 years: stood at $7.7 million in 2021, then soared by 44.32% to $11.1 million in 2022, then climbed by 19.07% to $13.3 million in 2023, then surged by 34.72% to $17.9 million in 2024, then gained by 24.46% to $22.2 million in 2025.
• Business Quant data shows MNPR's Interest Expenses at $22.2 million in Q4 2025, $110800.0 in Q3 2025, and $124090.0 in Q2 2025.